Inhibikase stock rises as FDA lifts clinical hold on Parkinson’s study

Headquarters of US Food and Drug Administration (FDA)

Grandbrothers/iStock Editorial via Getty Images

Inhibikase Therapeutics (NASDAQ:IKT) stock rose ~12% on Wednesday after the company said that the U.S. Food and Drug Administration (FDA) lifted a clinical hold on IkT-148009 in Parkinson’s disease (PD).

In November, the FDA had placed

Source link

5 Trading strategies to make money

Looking to boost your trading profits?

Get you copy of our FREE Ebook Now !!!